孙学明,吴慧,卢晓旭,徐靖,王姝娟,程欣宇,闫朱敏,黄蓉.奈达铂对比顺铂化疗联合IMRT治疗非高发区局部晚期鼻咽癌临床观察[J].中华放射医学与防护杂志,2018,38(11):836-841
奈达铂对比顺铂化疗联合IMRT治疗非高发区局部晚期鼻咽癌临床观察
Comparison of nedapaltin and cispaltin chemotherapy combined with intensity modulated radiotherpy for locally advanced nasopharygeal carcinoma patients in unendemic area
投稿时间:2018-07-25  
DOI:10.3760/cma.j.issn.0254-5098.2018.11.007
中文关键词:  鼻咽肿瘤  同期放化疗  调强适形放疗  辅助化疗  预后
英文关键词:Nasopharygeal neoplasms  Concurrent chemoradiotherapy  Intensity-modulated radiotherapy  Adjuvant chemotherapy  Prognosis
基金项目:河南省科技攻关计划项目(152102310156)
作者单位E-mail
孙学明 450008 郑州大学附属肿瘤医院 河南省肿瘤医院放疗科  
吴慧 450008 郑州大学附属肿瘤医院 河南省肿瘤医院放疗科 wuhui7008@126.com 
卢晓旭 450008 郑州大学附属肿瘤医院 河南省肿瘤医院放疗科  
徐靖 450008 郑州大学附属肿瘤医院 河南省肿瘤医院放疗科  
王姝娟 450008 郑州大学附属肿瘤医院 河南省肿瘤医院放疗科  
程欣宇 450008 郑州大学附属肿瘤医院 河南省肿瘤医院放疗科  
闫朱敏 450008 郑州大学附属肿瘤医院 河南省肿瘤医院放疗科  
黄蓉 450008 郑州大学附属肿瘤医院 河南省肿瘤医院放疗科  
摘要点击次数: 3020
全文下载次数: 1525
中文摘要:
      目的 对比奈达铂与顺铂为基础的化疗联合调强适形放疗(IMRT)治疗非高发区局部晚期鼻咽癌的疗效及不良反应。方法 回顾性分析2014年1月至2016年7月初治的行根治性放疗的Ⅲ~ⅣB期鼻咽癌患者,筛选出62对患者(奈达铂组和顺铂组各62例)进行配对分析。奈达铂组采用奈达铂3周方案同期化疗2~3个疗程,序贯奈达铂+氟尿嘧啶方案辅助化疗2~3个疗程。顺铂组采用顺铂3周方案同期化疗2~3个疗程,序贯顺铂+氟尿嘧啶方案辅助化疗2~3个疗程。比较两组患者各项生存率及急性不良反应。结果 奈达铂组和顺铂组的2年总生存率(OS)分别为89.9% 和91.1%,无局部复发生存率(LRFS)为90.5%和93.5%,无区域复发生存率(RRFS)为96.4% 和96.0%,无远处转移生存率(DMFS)为85.9% 和90.3%,差异均无统计学意义(P>0.05)。急性不良反应方面,同期放化疗及辅助化疗期间,奈达铂组3~4级呕吐发生率均较顺铂组明显降低,辅助化疗期间,奈达铂组3~4级血小板减少的发生率较顺铂组明显升高。结论 对于非高发区局部晚期鼻咽癌患者,以奈达铂为基础的化疗联合IMRT2年各项生存率与顺铂组相似,且3~4级呕吐发生率较顺铂组明显降低。对于无法耐受顺铂治疗的患者,奈达铂也许可作为替代化疗方案。
英文摘要:
      Objective To compare the efficacy and toxicity of nedaplatin and cispaltin chemotherapy combined with intensity modulated radiotherpy (IMRT) in the treatment of locally advanced nasopharygeal carcinoma (NPC) patients in unendemic area. Methods From January 2014 to July 2016, sixty-two pairs of patients with stage Ⅲ-ⅣB NPC patients who underwent radical radiotherapy were selected for pair analysis (nedaplatin group and cisplatin group, 62 cases for each group). The nedaplatin group was treated with IMRT concurrent with nedaplatin at a dose of 100 mg/m2 every three-weeks for 2-3 cycles, and sequential adjuvant chemotherapy of nedaplatin + fluorouracil regimen for 2 to 3 courses. The cisplatin group was treated with IMRT concurrent with cisplatin at a dose of 80 mg/m2 every three-weeks for 2-3 cycles, and sequential adjuvant chemotherapy of cisplatin + fluorouracil regimen for 2 to 3 courses. Results The 2-year overall survival (OS) of nedaplatin group and cisplatin group was 89.9% and 91.1%, local recurrence free survival (LRFS) 90.5% and 93.5%, regional recurrence free survival (RRFS) 96.4% and 96.0%, and distant metastasis free survival (DMFS) 85.9% and 90.3%, respectively. There were no significant differences between nedaplatin group and cisplatin group(P>0.05). In the occurrence of acute toxicity, during concurrent chemoradiotherapy and adjuvant chemotherapy, the incidence of grade 3-4 vomiting in nedaplatin group was significantly lower than that in cisplatin group. During adjuvant chemotherapy, the incidence of grade 3-4 thrombocytopenia in nedaplatin group was significantly higher than that in cisplatin group. Conclusions For NPC patients with stage Ⅲ-ⅣB in unendemic area, the 2-year survival rates of nedaplatin group was silimiar to cisplatin group, while the incidence of grade 3-4 vomiting was significantly lower than that in cisplatin group. Nedaplatin maybe an alternative chemotherapy for patients who cannot tolerate cisplatin chemotherapy.
HTML  查看全文  查看/发表评论  下载PDF阅读器
关闭